Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy
Shuang Xiang, Jie Wang, Huisi Huang, Zuqin Wang, Xiaojuan Song, Yang Zhou, Feng Jin, Xun He, Zhimin Zhang, Zhengchao Tu, Ke Ding, Zhang Zhang, Xiaoyun Lu
Topics & Concepts
Trk receptorChemistryMutantWild typeIC50Tropomyosin receptor kinase APharmacologyCancer researchStereochemistryIn vitroReceptorBiochemistryMedicineNeurotrophinGeneMelanoma and MAPK PathwaysProtein Degradation and InhibitorsHER2/EGFR in Cancer Research